Publications

Search our bibliography using the filters on the right-hand side.

Displaying 201 through 250 of 325 publications.

Candrilli SD, Manjunath R, Davis KL, Gidal BE. The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy. Epilepsy Res. 2010 Oct 1;91(2-3):260-6.

Jackson D, Earnshaw SR, Farkouh R, Schwamm L. Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective. Am J Neuroradiol. 2010 Oct 1;31(9):1669-74.

Hollis KA, Calingaert B, Price M, Andrews E, Moy L, Kooijmans M, Cristiano L, Bozic C. Tysabri TOUCH prescriber program risk management program (RiskMAP) surveys. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom.

Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010 Aug 6;363(6):542-51.

Fehnel SE, Coon CD, Davis KH, Runken MC, Cady RK. Development and Psychometric Evaluation of the Migraine Completeness of Response Survey (CORS). Poster presented at the 52nd Annual Scientific Meeting of the American Headache Society; June 2010. [abstract] Headache. 2010 Aug; 50(s1):S49-50.

Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010 Aug;26(8):1957-65. doi: 10.1185/03007995.2010.493788

Rinaldi F, Hwang S, Strutton D, Earnshaw S, Farkouh R. Clinical and economic impact of 13-valent pneumococcal conjugate vaccination in Singapore and Hong Kong. Poster presented at the 2010 ISPOR 15th Annual International Meeting; June 2, 2010.

Jackson D, Earnshaw S, Farkouh RA, Schwamm LH. Cost-effectiveness of perfusion imaging with computed tomography to identify patients for intravenous thrombolysis: a hospital perspective. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A175.

Borah B, Sacco P, Zarotsky V. Predictors of adherence among alzheimer's disease patients receiving oral therapy: results of a retrospective database analysis. Presented at the American Academy of Neurology; April 2010. Toronto, Canada.

Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.

Jackel J, Davis KL, Patel A. Stroke in the long-term care setting: patient characteristics and medication treatment. Poster presented at the Annual Meeting of the American Society of Consultant Pharmacists; November 2009.

Twiss J, Doward LC, McKenna SP, Eckert B. Interpreting scores on the multiple sclerosis-specific PRIMUS and U-FIS outcome measures. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A373. doi: 10.1016/S1098-3015(10)74836-1

Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct 1;36(10):2330-4.

Farkouh R, Wilson M, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with other first-line treatment options for early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A369.

Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.

Rothman KJ. Health effects of mobile telephones. Epidemiology. 2009 Sep 1;20(5):653-5.

Gilsenan A, Andrews EB, Calingaert B, Crozier DA, Vanderpuije A. Evaluation of current risk evaluation and mitigation strategies. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 16, 2009. Providence, RI.

Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin SA. Measurement properties of the medical outcomes study sleep scale in patients with fibromyalgia. Sleep Med. 2009 Aug;10(7):766-70.

Martin S, Chandran A, Zografos L, Zlateva G. Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales. Health Qual Life Outcomes. 2009 Jul 1;7:64.

Earnshaw SR, Wilson M, Mauskopf J, Joshi AV. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Value Health. 2009 Jun 1;12(4):507-20.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009 Jun 1;7(2):91-108.

Cappelleri JC, Bushmakin AG, McDermott AM, Sadosky AB, Petrie CD, Martin SA. Psychometric properties of a single-item scale to assess sleep-quality among individuals with fibromyalgia. Health Qual Life Outcomes. 2009 Jun;7(54):54.

Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009 May 1;40(5):1710-20.

Farkouh RA, Wilson MR, Tarrants M, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline versus ropinirole extended release in delaying levodopa in the treatment of early parkinson's disease in the United States. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 2009 May; 12(3):A192.

Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, Murray MD. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy. 2009 Mar;29(3):255-62.

Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of nonadherence with antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav. 2009 Feb;14(2):324-9. doi: 10.1016/j.yebeh.2008.10.021.

Ehrenstein V, Pedersen L, Grijota M, Lauge Nielsen G, Rothman KJ, Toft Sorensen H. Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth. 2009;9(1):14.

Le TK, Roskell NS, Mladsi DM, Mitra D, Shannon PR, Wilson AG, Juniper MD. Database analysis to estimate medical and pharmacotherapy resource utilization and costs of fibromyalgia prior to and following diagnosis in the United Kingdom primary care setting. Poster presented at the 25th Annual Meeting of the American Academy of Pain Medicine; January 2009. Hawaiian Village, Honolulu, HI.

Martin S, Chandran A, Zografos L, Zlateva G, Sadosky A. Content validity of the sleep quality numeric rating scale (NRS) and the medical outcomes study sleep scale (MOS-sleep) in patients with fibromyalgia (Fm). Sleep. 2009 Jan 1;32(Suppl. S):A327.

Manjunath RY, Davis KL, Candrilli SD, Ettinger AE. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav. 2009 Jan;14(2):372-8.

Viala-Danten M, Martin SA, Guillemin I, Hays RD. Evaluation of the reliability and validity of the medical outcomes study sleep scale in patients with painful diabetic peripheral neuropathy during an international clinical trial. Health Qual Life Outcomes. 2008 Dec;6(113).

Davis KL, Manjunath R, Ettinger AB. The association between attention deficit and psychiatric disorders and adherence to antiepileptic drug treatment in pediatric epilepsy. Poster presented at the 62nd Annual Meeting of the American Epilepsy Society; December 2008.

Gidal BE, Candrilli SD, Davis KL, Manjunath R. The association between antiepileptic drug and hmg-coa reductase inhibitor interactions and health outcomes in epilepsy. Poster presented at the 62nd Annual Meeting of the American Epilepsy Society; December 2008.

Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, Martin SA. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008 Oct;73(1):114-20.

Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008 Sep;9(9):792-805.

Mladsi DM, Juniper MD, Roskell NS, Mitra D, Shannon PR, Wilson A, Garcia Cebrian A, Le KT. Pharmacological management of fibromyalgia in UK primary care. Poster presented at the19th Annual Clinical Meeting of the American Academy of Pain Management; September 2008. Nashville, TN.

Berger A, Sadosky A, Edelsberg J, Dukes E, Martin SA, Oster G. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin. 2008 Sep;24(9):2489-99.

Mease P, Arnold L, Crofford L, Williams D, Russell IJ, Humphrey L, Abetz L, Martin SA. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient delphi exercises. Arthritis Care Res (Hoboken). 2008 Jul;59(7):952-60.

Fehnel S, Zografos L, Curtice T, Shah H, McLeod L. The burden of restless legs syndrome: an assessment of work productivity, sleep, psychological distress, and health status among diagnosed and undiagnosed individuals in an internet-based panel. Patient. 2008 Jul 1;1(3):201-10.

Mladsi DM, Juniper MD, Roskell NS, Mitra D, Shannon PR, Wilson AG. The pharmacological management of fibromyalgia syndrome in the UK primary care setting. Presented at the Annual Congress of the European League Against Rheumatism; June 2008. Paris, France.

Juniper MD, McCrink L, Mladsi DM, Le TK. The burden of fibromyalgia in France, Germany, Italy, Spain, and the UK: a literature-based review. Poster presented at the Annual Congress of the European League Against Rheumatism; June 2008. Paris, France.

Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, Sharma U. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. J Pain. 2008 Jun;136(3):419-31.

McAfee AT, Holdridge KC, Johannes CB, Hornbuckle K, Walker AM. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr Drug Saf. 2008 May 1;3(2):123-31.

Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008 Mar 1;49(3):446-54.

Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.

Edin HM, DiBenedetti D, Hill CD. Adherence among patients with Parkinson's Disease taking ropinirole immediate release at least three times daily. Poster presented at the Movement Disorders Society; June 13, 2008. [abstract] Mov Disord. 2008; 23:S344-5.

Doward L, Karim S, Ramanna G, Petit T, Burns A. Development of the Dementia Quality of Life questionnaire (D-QOL): uK version. Aging Ment Health. 2008 Jan;12(1):144-8.

Ettinger AE, Candrilli SD, Davis KL, Manjunath R. Prevalence and cost impact of noncompliance with antiepileptic drugs in an elderly managed care population. Poster presented at the 61st Annual Meeting of the American Epilepsy Society; December 2007.

Davis KL, Manjunath R, Candrilli SD, Ettinger AB. Impact of compliance with antiepileptic drugs on risk of serious breakthrough seizure in an adult managed care population with epilepsy. Poster presented at the 61st Annual Meeting of the American Epilepsy Society; December 2007.

Graham JB, Earnshaw SR, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A381.